Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1288

1.

Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening.

Cohen PA, Flowers N, Tong S, Hannan N, Pertile MD, Hui L.

BMC Med. 2016 Aug 24;14(1):126. doi: 10.1186/s12916-016-0667-6.

2.

Identification of therapeutic targets applicable to clinical strategies in ovarian cancer.

Kim MK, Caplen N, Chakka S, Hernandez L, House C, Pongas G, Jordan E, Annunziata CM.

BMC Cancer. 2016 Aug 24;16:678. doi: 10.1186/s12885-016-2675-5.

3.

Gene Coexpression Analyses Differentiate Networks Associated with Diverse Cancers Harboring TP53 Missense or Null Mutations.

Oros Klein K, Oualkacha K, Lafond MH, Bhatnagar S, Tonin PN, Greenwood CM.

Front Genet. 2016 Aug 3;7:137. doi: 10.3389/fgene.2016.00137. eCollection 2016.

4.

AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer.

Svoboda M, Meshcheryakova A, Heinze G, Jaritz M, Pils D, Castillo-Tong DC, Hager G, Thalhammer T, Jensen-Jarolim E, Birner P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Zimmermann P, Zeillinger R, Mechtcheriakova D.

BMC Genomics. 2016 Aug 16;17(1):643. doi: 10.1186/s12864-016-3001-y.

5.

Management of relapsed ovarian cancer: a review.

Giornelli GH.

Springerplus. 2016 Jul 28;5(1):1197. doi: 10.1186/s40064-016-2660-0. eCollection 2016. Review.

6.

Somatic mutation profiles in primary colorectal cancers and matching ovarian metastases: Identification of driver and passenger mutations.

Crobach S, Ruano D, van Eijk R, Schrumpf M; PALGA group, Fleuren G, van Wezel T, Morreau H.

J Pathol Clin Res. 2016 Apr 15;2(3):166-74. doi: 10.1002/cjp2.45. eCollection 2016 Jul.

7.

Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.

Cheon DJ, Walts AE, Beach JA, Lester J, Bomalaski JS, Walsh CS, Ruprecht Wiedemeyer W, Karlan BY, Orsulic S.

J Pathol Clin Res. 2014 Nov 5;1(1):41-53. doi: 10.1002/cjp2.4. eCollection 2015 Jan.

8.

A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis.

Yin X, Wang X, Shen B, Jing Y, Li Q, Cai MC, Gu Z, Yang Q, Zhang Z, Liu J, Li H, Di W, Zhuang G.

Sci Rep. 2016 Aug 8;6:31079. doi: 10.1038/srep31079.

9.

Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.

Iwanicki MP, Chen HY, Iavarone C, Zervantonakis IK, Muranen T, Novak M, Ince TA, Drapkin R, Brugge JS.

JCI Insight. 2016 Jul 7;1(10). pii: e86829.

10.

A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma.

Liu LW, Zhang Q, Guo W, Qian K, Wang Q.

Biomed Res Int. 2016;2016:6945304. doi: 10.1155/2016/6945304. Epub 2016 Jul 5.

11.

Joint analysis of multiple high-dimensional data types using sparse matrix approximations of rank-1 with applications to ovarian and liver cancer.

Okimoto G, Zeinalzadeh A, Wenska T, Loomis M, Nation JB, Fabre T, Tiirikainen M, Hernandez B, Chan O, Wong L, Kwee S.

BioData Min. 2016 Jul 29;9:24. doi: 10.1186/s13040-016-0103-7. eCollection 2016.

12.

Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice.

Dong A, Lu Y, Lu B.

J Cancer. 2016 Jul 5;7(11):1441-51. doi: 10.7150/jca.15556. eCollection 2016. Review.

13.

Genetic and molecular changes in ovarian cancer.

Hollis RL, Gourley C.

Cancer Biol Med. 2016 Jun;13(2):236-47. doi: 10.20892/j.issn.2095-3941.2016.0024.

14.

Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies.

Hocking J, Mithraprabhu S, Kalff A, Spencer A.

Cancer Biol Med. 2016 Jun;13(2):215-25. doi: 10.20892/j.issn.2095-3941.2016.0025.

15.

Allele-Specific Quantification of Structural Variations in Cancer Genomes.

Li Y, Zhou S, Schwartz DC, Ma J.

Cell Syst. 2016 Jul;3(1):21-34. doi: 10.1016/j.cels.2016.05.007. Epub 2016 Jul 21.

PMID:
27453446
16.

Diagnostic potential of tumor DNA from ovarian cyst fluid.

Wang Y, Sundfeldt K, Mateoiu C, Shih IeM, Kurman RJ, Schaefer J, Silliman N, Kinde I, Springer S, Foote M, Kristjansdottir B, James N, Kinzler KW, Papadopoulos N, Diaz LA, Vogelstein B.

Elife. 2016 Jul 15;5. pii: e15175. doi: 10.7554/eLife.15175.

17.

Peroxiredoxin 1 interacts with and blocks the redox factor APE1 from activating interleukin-8 expression.

Nassour H, Wang Z, Saad A, Papaluca A, Brosseau N, Affar el B, Alaoui-Jamali MA, Ramotar D.

Sci Rep. 2016 Jul 8;6:29389. doi: 10.1038/srep29389.

18.

Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma.

Ezzati M, Abdullah A, Shariftabrizi A, Hou J, Kopf M, Stedman JK, Samuelson R, Shahabi S.

Int Sch Res Notices. 2014 Oct 29;2014:953509. doi: 10.1155/2014/953509. eCollection 2014. Review.

19.

Cancer Markers Selection Using Network-Based Cox Regression: A Methodological and Computational Practice.

Iuliano A, Occhipinti A, Angelini C, De Feis I, LiĆ³ P.

Front Physiol. 2016 Jun 17;7:208. doi: 10.3389/fphys.2016.00208. eCollection 2016.

20.

Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.

de Leon M, Cardenas H, Vieth E, Emerson R, Segar M, Liu Y, Nephew K, Matei D.

Gynecol Oncol. 2016 Sep;142(3):539-47. doi: 10.1016/j.ygyno.2016.06.017. Epub 2016 Jun 30.

PMID:
27374141
Items per page

Supplemental Content

Write to the Help Desk